Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)

Historical Holders from Q4 2022 to Q2 2025

Symbol
ACRV on Nasdaq
CUSIP
004890109
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
31.2M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
17.8M
Holdings value
$21.2M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
52
Number of buys
26
Number of sells
-39
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sands Capital Life Sciences Pulse Fund II, L.P. 6.8% $2.82M 2.12M Sands Capital Life Sciences Pulse Fund II, L.P. Jun 30, 2025
CITADEL ADVISORS LLC 6% $3.05M 1.9M Kenneth Griffin Mar 31, 2025

Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q2 17.8M $21.2M -$10.3M $1.19 52
2025 Q1 22.5M $45.7M -$2.11M $2.03 60
2024 Q4 23.3M $140M -$971K $6.02 60
2024 Q3 23M $161M -$2.68M $7.00 51
2024 Q2 23.5M $136M +$47.4M $5.80 51
2024 Q1 15.2M $109M +$3.45M $7.15 45
2023 Q4 10.7K $52.5K $4.92 1
2023 Q3 15.1M $144M -$326K $9.56 43
2023 Q2 15.1M $196M -$1.15M $12.96 40
2023 Q1 15.2M $191M +$6.82M $12.69 39
2022 Q4 14.5M $166M +$165M $11.52 17